82 results on '"Zent, Clive"'
Search Results
2. Risk of New-Onset Atrial Fibrillation Associated With Targeted Treatment of Lymphoma
3. Healthcare Utilization Disparities of Adolescent and Young Adults Compared to the Older Lymphoma Population
4. Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia
5. Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience
6. miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels
7. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
8. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience
9. Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia
10. Recurrent Fevers, Cough, and Pulmonary Opacities in a Middle-Aged Man
11. B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome
12. Low Dose Rituximab Efficiently Clears Circulating CLL Cells and Maintains Sensitivity to Antibody Dependent Cellular Phagocytosis (ADCP)
13. DNA Methylation-Based Classification of Hairy Cell Leukemia and Splenic B Cell Lymphoma
14. Splenic B Cell Lymphoma Innate Immune Cells: Detection of Red Versus White Pulp Lymphoma Differences in NK Cell Populations By High-Parameter Flow Cytometry
15. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
16. Metaphase cells with normal G-bands have cryptic interstitial deletions in 13q14 detectable by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia
17. The Role of Splenectomy in Management of Splenic B-Cell Lymphomas
18. Rituximab Induces an Inflammatory Cytokine Response with Increased IP-10 (CXCR10) in Patients with Infusion Reactions
19. Rapid Tumor Debulking of Relapsed/Refractory CLL Patients By PI3Kδ Inhibition and Anti-CD20 Monoclonal Antibody Treatment
20. Innate Immune Microenvironment of Indolent B Cell Splenic Lymphomas: Role in Diagnosis and Treatment
21. PO-654-04 RISK OF NEW ONSET ATRIAL FIBRILLATION ASSOCIATED WITH CONTEMPORARY TREATMENT OF LYMPHOMA
22. Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9
23. A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
24. Arrhythmia Burden in Patients with Indolent Lymphoma
25. Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL)
26. Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in CLL: Results from a Large Multi-Center Study of 683 US-Patients
27. The Role of Microrna-150 in the Prognosis and Transformation of Follicular Lymphoma
28. Toxicities and Outcomes of Ibrutinib-Treated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients
29. High Risk of Infections in Chronic Lymphocytic Leukemia Patients Treated with B-Cell Receptor Inhibitors
30. Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab
31. Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study
32. Clinical and Translational Results from a Phase II Trial of Imprime PGG, Alemtuzumab, and Rituximab in the Early Treatment of Patients with High Risk Chronic Lymphocytic Leukemia
33. Loss of TP53 is due to rearrangements involving chromosome region 17p10∼p12 in chronic lymphocytic leukemia
34. Hodgkin Transformation of Chronic Lymphocytic Leukemia (CLL): Mayo Clinic Experience
35. The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087 Alliance)
36. Early Treatment of High Risk Chronic Lymphocytic Leukemia with Alemtuzumab, Rituximab, and PGG Beta Glucan: A Phase I Clinical Trial
37. Alemtuzumab Use and Survival After Reduced Intensity Allogeneic Stem Cell Transplantation in High-Risk Chronic Lymphocytic Leukemia (CLL),
38. Infectious Complications Among Individuals with Monoclonal B-Cell Lymphocytosis (MBL): A Prospective Case-Control Study of Newly Diagnosed Patients,
39. Ofatumumab Based Chemoimmunotherapy (CIT) for Patients with Previously Untreated CLL,
40. Lenalidomide Consolidation Appears to Prolong Time to Retreatment After First-Line Chemoimmunotherapy for Patients with Previously Untreated CLL,
41. FISH Scoring for CLL: Comparison of Methods That Assess Round Versus Non-Round Nuclei,
42. In Patients Newly Diagnosed with Chronic Lymphocytic Leukemia the Absolute Monocyte Count At Presentation Is Directly Associated with Disease Progression Independently From Rai Staging or Cytogenetics
43. Resistance to Complement Dependent Cytotoxicity in CLL Cells From Patients Treated with Ofatumumab
44. Pentostatin, Alemtuzumab, and Low Dose Rituximab Is Effective Therapy for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL)
45. Axl Receptor Tyrosine Kinase Signaling Pathway and the p53 Tumor Suppressor Protein Exist In A Novel Regulatory Loop In B-Cell Chronic Lymphocytic Leukemia Cells
46. 5.24 Pentostatin, Alemtuzumab, and Low-Dose Rituximab Is Effective Therapy for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
47. 5.15 Resistance to Complement-Dependent Cytotoxicity in Chronic Lymphocytic Leukemia Cells from Patients Treated with Ofatumumab
48. 4.15 FISH for CLL – A More Sensitive Scoring Method
49. 3.13 Infectious Complications Among Individuals with Monoclonal B-Cell Lymphocytosis (MBL): A Community-based Cohort Study of Newly Diagnosed Patients Compared to Controls
50. 3.12 The Prevalence of Serious Infections in a Community-Based Cohort of Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) Compared to Controls: Results of a Cohort Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.